Recent News

• 02.10.2026 - Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation
• 02.10.2026 - Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026
• 12.23.2025 - Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives
• 12.23.2025 - Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests
• 12.23.2025 - Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives
• 12.23.2025 - Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests
• 12.15.2025 - Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances

Recent Filings

• 01.26.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.23.2026 - EFFECT Notice of Effectiveness
• 01.23.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.15.2026 - F-1 Registration statement for certain foreign private issuers
• 12.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.23.2025 - EX-99.1 EX-99.1
• 12.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.23.2025 - EX-99.1 EX-99.1
• 12.23.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 12.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]